Anteris Technologies Global Corp. · NASDAQ:AVR
Anteris Technologies Global — TVT 2023
13 slides from Anteris Technologies Global's conference presentation, Oct 13, 2023
Slide 1: DurAVR THV: First-In-Class Biomimetic TAVR – FIH Study Results
DurAVR™ THV: The First-In-Class Biomimetic TAVR to Restore Normal Aortic Flow Hemodynamics – FIH Study Results Christopher U. Meduri, MD MPH Karolinska University Hospital, Stockholm (Sweden)
Slide 2: Disclosure of Relevant Financial Relationships
Disclosure of Relevant Financial Relationships Within the prior 24 months, I have had a relevant financial relationships with the ineligible companies listed below. Nature of Financial Relationship Ineligible Company Chef Medical Officer Anteris Technologies Grant/Research Support Boston Scientific
Slide 3: DurAVR: A First-in-class Biomimetic Transcatheter Aortic Valve
DurAVR™: A First-in-class Biomimetic Transcatheter Aortic Valve DurAVR™ THV System DurAVR™ THV Biomimetic valve Native-like Balloon-expandable shaped valve large cells ADAPT® Anti-Calcification Commissure Tissue Engineering Process alignment Single-piece PVL skirt leaflet design ComASUR™ TF Delivery
Slide 4: Biomimetic Design leads to improved hemodynamics and flow
• Biomimetic Design leads to improved hemodynamics and flow Sapien 3 Hydrodynamics DurAVRTM THV Hydrodynamics Evolut Hydrodynamics EOA: 2.30 cm2 EOA: 2.83 cm2 EOA: 2.41 cm2 Gradient: 8.8 mmHg Gradient: 5.9 mmHg Gradient: 8.3 mmHg TCT 2022, Presented by Janar Sathananthan, MD
Slide 5: DurAVR FIH Study Design
DurAVR™ FIH Study Design 20 patients enrolled Design (Nov ’21, May ’22, Apr ’23) in Tbilisi (Georgia) Prospective, non-randomized, single-arm, single-center DurAVR™ THV successful implants 100% (n=20) Purpose Evaluate the safety and feasibility of the DurAVR™ Clinical follow-up at 30 days THV System
Slide 6: Baseline and Procedural Characteristics
Baseline and Procedural Characteristics Baseline characteristics n = 20 Procedural characteristics n = 20 Age (years) 74.25 ± 5.72 Approach Transfemoral (TF) 14 (70) Gender (female) 16 (80) Transaortic (TAo)* 5 (25) STS Prom (%) 2.25 ± 0.90 Transcarotid (TC) 1 (5) Area-derived annulus diameter (mm)
Slide 7: Procedural Outcomes
Procedural Outcomes 100% Implant Success (n = 20) No device-related complications No moderate or severe paravalvular leak (PVL) One mild-moderate central AR (early case before valve sizing optimization) No significant PVL and no central AR post- Balloon-expandable delivery Large open-cell ge
Slide 8: Consistent Excellent Hemodynamic Results up to Year 1
Consistent Excellent Hemodynamic Results up to 1 Year Mean annulus: 22.73 mm (n = 20) 2.5 60 53.34 2.02 1.98 1.93 50 2.0 40 MPG (mmHg) 1.5 EOA (cm2) 30 1.0 0.69 20 0.5 10 8.50 8.58 9.22 0.0 0 Baseline 30 Days 6 Months 1 Year (n=20) (n=20) (n=13) (n=12) EOA MPG EOA = Effective Orifice Area MPG = Mean
Slide 9: DurAVR THV FIH – April 2023 cohort
DurAVR™ THV FIH – April 2023 cohort Baseline characteristics n=7 EOA (cm2) MPG (mmHg) Age (years) 74.86 ± 4.60 2.5 100 Gender (female) 6 (86) 2.0 80 STS Prom (%) 2.07 ± 0.47 1.5 60 Area-derived annulus diameter (mm) 22.33 ± 1.51 1.0 40 NYHA class 0.5 20 II 5 (71) 0.0 0 III 2 (29) Baseline 30 Days Ba
Slide 10: Favorable Safety Profile in All Patients at Latest Follow-up
Favorable Safety Profile in All Patients at Latest Follow-up One non-cardiac death (car accident) on POD 343 One access site complication (resolved on POD 1) One new pacemaker in a patient with baseline RBBB and LAFB (POD 6) No stroke No minor or major bleeding No reoperation or reinterv
Slide 11: DurAVR: the First-In-Class Biomimetic THV To Restore Normal Aortic Flow
DurAVR™: the First-In-Class Biomimetic THV To Restore Normal Aortic Flow Healthy Aortic Valve Post DurAVR™ THV FD = 10 cm FD = 14 cm FRR = 1% FRR = 4% (n=5) (n=5) Normal Valve flow vs DurAVR™: No significant difference in flow (p > 0.05) Impaired Aortic Flow Severe AS Sapien 3 Evolut R CEP Magna Eas
Slide 12: Anteris DurAVR First-in-Class Biomimetic THV
Anteris DurAVR™ First-in-Class Biomimetic THV Kodali SK. et al., EuroIntervention, May 2023;19. Online ahead of print. DOI: 10.4244/EIJ-D-23-00282
Slide 13: THANK YOU!
THANK YOU!